Journal of Clinical Oncology, Vol 22, No 16 (August 15), 2004: pp. 3345-3349
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.12.177
The Microanatomic Location of Metastatic Melanoma in Sentinel Lymph Nodes Predicts Nonsentinel Lymph Node Involvement
D.J. Dewar,
B. Newell,
M.A. Green,
A.P. Topping,
B.W.E.M. Powell,
M.G. Cook
From the Department of Plastic and Reconstructive Surgery, St George's Hospital, London; and Department of Histopathology, Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
Address reprint requests to Donald Dewar, MB, BS, Department of Histopathology, Royal Surrey County Hospital, Egerton Rd, Guildford, Surrey GU2 7XX, United Kingdom; e-mail: DJDewar{at}aol.com
PURPOSE: Sentinel node biopsy is now widely accepted as the most accurate prognostic indicator in melanoma, and is important in guiding management of patients with clinical stage I or II disease. Patients with a positive sentinel node have conventionally undergone completion lymphadenectomy (CLND) of the involved basin, but only 20% have involvement beyond the sentinel node, suggesting that CLND may be unnecessary for the other 80% of patients. This study seeks to identify criteria that might be used to be more restrictive in selecting those who should undergo CLND.
METHODS: A total of 146 patients were identified who had had a positive sentinel node biopsy for malignant melanoma. Their sentinel nodes and lymphadenectomy specimens were re-evaluated pathologically. The metastatic melanoma in each sentinel node was assessed according to its microanatomic location within the node (subcapsular, combined subcapsular and parenchymal, parenchymal, multifocal, or extensive), and this was correlated with the presence of involved nonsentinel nodes in the CLND. The depth of the metastases from the sentinel node capsule was also recorded.
RESULTS: The metastatic deposits in the sentinel node were subcapsular in 26.0% of patients. None of these patients had any nonsentinel nodes involved on CLND. In the patients whose sentinel node metastases had a different microanatomic location, the rate of nonsentinel node involvement was 22.2% overall.
CONCLUSION: The microanatomic location of metastases within sentinel nodes predicts nonsentinel lymph node involvement. In patients with only subcapsular deposits in the sentinel node, it is possible that CLND could safely be avoided.
Presented in part at the British Association of Plastic Surgeons Winter Meeting, London, United Kingdom, November 2729, 2002; the EORTC Melanoma Group Spring Meeting, Paris, France, April 1112, 2003; and the Third Research Meeting on Melanoma, Milan, Italy, May 2527, 2003.
Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. A. Voit, A. C.J. van Akkooi, G. Schafer-Hesterberg, A. Schoengen, P. I.M. Schmitz, W. Sterry, and A. M.M. Eggermont
Rotterdam Criteria for Sentinel Node (SN) Tumor Burden and the Accuracy of Ultrasound (US) -Guided Fine-Needle Aspiration Cytology (FNAC): Can US-Guided FNAC Replace SN Staging in Patients With Melanoma?
J. Clin. Oncol.,
October 20, 2009;
27(30):
4994 - 5000.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Voit, G. Schafer-Hesterberg, M. Kron, A. C.J. van Akkooi, J. Rademaker, A. Lukowsky, A. Schoengen, M. Schwurzer-Voit, W. Sterry, M. Krause, et al.
Impact of Molecular Staging Methods in Primary Melanoma: Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) of Ultrasound-Guided Aspirate of the Sentinel Node Does Not Improve Diagnostic Accuracy, But RT-PCR of Peripheral Blood Does Predict Survival
J. Clin. Oncol.,
December 10, 2008;
26(35):
5742 - 5747.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Gershenwald, R. H.I. Andtbacka, V. G. Prieto, M. M. Johnson, A. H. Diwan, J. E. Lee, P. F. Mansfield, J. N. Cormier, C. W. Schacherer, and M. I. Ross
Microscopic Tumor Burden in Sentinel Lymph Nodes Predicts Synchronous Nonsentinel Lymph Node Involvement in Patients With Melanoma
J. Clin. Oncol.,
September 10, 2008;
26(26):
4296 - 4303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M G Cook and S Di Palma
Pathology of sentinel lymph nodes for melanoma
J. Clin. Pathol.,
August 1, 2008;
61(8):
897 - 902.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Scolyer, R Murali, J. Gershenwald, A. Cochran, and J. Thompson
Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell
Ann. Onc.,
April 1, 2007;
18(4):
806 - 808.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. van Akkooi, J. de Wilt, C Verhoef, P. Schmitz, A. van Geel, A. Eggermont, and M Kliffen
Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?
Ann. Onc.,
October 1, 2006;
17(10):
1578 - 1585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Cascinelli, E. Bombardieri, R. Bufalino, T. Camerini, A. Carbone, C. Clemente, L. Lenisa, L. Mascheroni, A. Maurichi, E. Pennacchioli, et al.
Sentinel and Nonsentinel Node Status in Stage IB and II Melanoma Patients: Two-Step Prognostic Indicators of Survival
J. Clin. Oncol.,
September 20, 2006;
24(27):
4464 - 4471.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Lejeune
What is the impact of sentinel node biopsy in the management of cancer?
Ann. Onc.,
August 1, 2005;
16(8):
1217 - 1218.
[Full Text]
[PDF]
|
 |
|
|